Article Text

Download PDFPDF

4CPS-209 Outcomes research on new tyrosine kinase inhibitors for non-small cell lung cancer
  1. P Cardoso1,
  2. M Capoulas1,
  3. T Lobo1,
  4. C Matos2,
  5. M Felizardo2,
  6. R Oliveira1,
  7. C Santos1
  1. 1Hospital Beatriz Ângelo, Hospital Pharmacy, Loures, Portugal
  2. 2Hospital Beatriz Ângelo, Pneumology, Loures, Portugal


Background Information technologies’ development and their integration in healthcare processes brought a major role in data generation to the pharmacy department. This massive data, also known as BIG DATA, is a powerful resource to initiate the measurement of healthcare outcomes related to dispensed drugs.

Purpose To access the main health outcomes of patients who received new tyrosine kinase inhibitors (TKI) and to develop a tool which provides real-life information based on the hospital environment to support the clinical decision.

Material and methods Every patient’s data was collected from the electronic medical records, from 2013 until 2017. For each patient, we recorded the outcome, the performance status and the duration of the treatment. The main analysis outcome was the overall survival (OS). The survival analysis was done using IBM SPSS Statistics.

Results Of the estimated glomerular filtration rate +patients, the majority received Erlotinib (n=42), either as second/third lines (n=30) or first line (n=12). The number of patients who took Gefitinib was smaller than Erlotinib (n=4). All the ALK +patients were treated with Crizotinib (n=5).

The observed median survival was 20.3 months for TKI in the line (n=21) and 3.2 months for the second/third lines (n=30), with p<0001. The median OS for Erlotinib in the first line was 21.3 months and 2.8 months for patients in the second/third lines. For Crizotinib, the observed median OS was 13.8 months, with an 18 month follow up. The sample was too small for the Gefitinib survival analysis.

Conclusion There is a major difference in the OS of TKIs used in the first versus second and further lines, which was expected since these patients present a higher ECOG PS than the first-line group. This study shows that the real-world data, even with small samples in single-centre studies, can be similar to clinical trials data, as our OS with Erlotinib is nearly identical to the one reported in the OPTIMAL study.

References and/or acknowledgements 1. Stokes LB, Rogers JW, Hertig JB, Weber RJ. Big data: implications for health system pharmacy. Hos Pharm 2016;51:599–603.

2. Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget2017:8:75712–26.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.